Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Manage your formulary budget
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
|Title:||Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors|
|Abstract:||The invention relates to a pharmaceutical composition comprising mirtazapine, a selective serotonin reuptake inhibitor (SSRI) and pharmaceutically acceptable auxiliaries. In particular the SSRI is selected from fluoxetine, fluvoxamine, citalopram, cericlamine, femoxetine, sertraline, paroxetine, ifoxetine, cyanodothiepin and litoxetine. The composition which can be used to treat depressant patients has less side effects than treatment of the patients with mirtazapine or the SSRI alone.|
|Inventor(s):||Nickolson; Victor Johannes (Hermelijnendreef, NL)|
|Assignee:||Akzo Nobel, N.V. (Arnhem, NL)|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Use;|
Field: Not categorized
Back Citations: 2nd percentile
Forward Citations: 5th percentile
|Patent Number||Expiration Date|
|5,977,099||November 02, 2011|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|96201703||Jun 19, 1996|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.